Polymyxin B Sulfate;Oxytetracycline Hcl

Verify with FDA CVM →

174 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
174
Total Reports
6
Deaths Reported
340.0%
Death Rate

Active Ingredients

Polymyxin B Sulfate;Oxytetracycline Hcl

Administration Routes

UnknownOphthalmicIntraocularTopicalOral

Species Affected

Unknown 83
Cat 71
Dog 17
Human 2
Goat 1

Most Affected Breeds

Unknown 85
Domestic Shorthair 39
Cat (other) 18
Domestic Mediumhair 4
Ragdoll 3
Chihuahua 3
Dog (unknown) 3
Retriever - Labrador 3
Bulldog 2
Siamese 2

Most Reported Reactions

Color, Abnormal 39
Underfilling, Container 17
Vomiting 16
Containers, Leaking 14
Containers, Damaged 12
Swelling around eye 10
Lack of efficacy - NOS 9
Lethargy (see also Central nervous system depression in 'Neurological') 8
Corneal ulcer 8
Swollen eye 7
Ocular discharge 7
Conjunctivitis 6

Outcome Breakdown

Ongoing
37 (40.2%)
Outcome Unknown
29 (31.5%)
Recovered/Normal
19 (20.7%)
Died
3 (3.3%)
Euthanized
3 (3.3%)
Recovered with Sequela
1 (1.1%)

Data Summary

Metric Value
Total adverse event reports 174
Reports involving death 6
Case-fatality rate (reported events) 340.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Polymyxin B Sulfate;Oxytetracycline Hcl Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 174 adverse event reports referencing Polymyxin B Sulfate;Oxytetracycline Hcl, including 6 reports in which the animal died — a 340.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Polymyxin B Sulfate;Oxytetracycline Hcl. Reported administration routes include Unknown, Ophthalmic, Intraocular, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Polymyxin B Sulfate;Oxytetracycline Hcl reports are Unknown (83 reports), Cat (71 reports), Dog (17 reports), with Unknown accounting for the largest share. Within those species, Unknown (85), Domestic Shorthair (39), Cat (other) (18) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Polymyxin B Sulfate;Oxytetracycline Hcl are Color, Abnormal (39), Underfilling, Container (17), Vomiting (16), Containers, Leaking (14). Of the 92 reports with a coded outcome, Ongoing is the leading category at 40.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Polymyxin B Sulfate;Oxytetracycline Hcl.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial